Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study. (December 2022)

• Record Type: Journal Article
• Authors: Owada, Yasuko; Okazaki, Mika; Ikeda, Toshiaki; Yamamoto, Ryuji; Minami, Kohtaro; Takahashi, Kenichi; Hirato, Tohru; Mita, Yoko; Yamamoto, Tatsuyoshi; Tanizawa, Kazunori; Sonoda, Hiroyuki; Sato, Yuji
• Is Part Of: Growth hormone & IGF research. Volume 67(2022)
• Publication Date: 2022-12
• Subjects: Long-acting human growth hormone -- Weekly administration -- Plasma drug concentration -- IGF-1 -- Growth hormone deficiency; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2022.101500
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Objective: Under clinical development for patients with growth hormone deficiency, JR-142 is a long-acting growth hormone with a half-life extended by fusion with modified serum albumin. We conducted a Phase 1 study to investigate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of once-weekly subcutaneous administrations of JR-142. The study consisted of two parts: an open-label single ascending dosing study (Part 1), and a randomized, placebo-controlled, assessor-blinded multiple ascending dosing study (Part 2). Design: A total of 31 healthy Japanese male participants were enrolled. In Part 1, seven of them received a single subcutaneous injection of JR-142 each at dosages of 0.15 mg/kg ( n = 1), 0.25 mg/kg ( n = 2), 0.5 mg/kg (n = 2), or 1.0 mg/kg (n = 2). In Part 2, one weekly subcutaneous injection of JR-142 at 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg or a placebo were given for four weeks to each of the other 24 participants (six in each group). Plasma JR-142 and serum insulin-like growth factor-1 (IGF-1) concentrations were measured for PK and PD assessments. Safety was evaluated on the basis of adverse events (AEs), laboratory tests, and other measures. Results: JR-142 induced dose-dependent increases in the maximum plasma JR-142 concentration (Cmax ) and the area under the plasma concentration-time curve from time 0 to τ (AUC0-τ ). A similar dose-response relationship was observed in serum IGF-1 concentrations. All trough IGF-1 levels were well sustained one week after the final administrations of JR-142 at the three dosages, while the peak concentrations of IGF-1 remained mildly elevated. No serious AEs were observed, and laboratory tests, including assessment of anti-drug antibodies, uncovered no significant safety issues. Conclusions: Once-weekly subcutaneous injections of JR-142 produced positive dose-dependent PK and PD profiles over the dosage range. Drug accumulation was observed after the four-week administration period but did not raise safety concerns, indicating that JR-142 is well-tolerated in healthy participants. The PD profiles observed in terms of IGF-1 concentrations were also positive, and we believe the encouraging results of this study warrant substantiation in further clinical trials in patients with GHD. Ethics: This clinical study was conducted at one investigational site in Osaka, Japan, where the clinical study and the non-clinical data of JR-142 were reviewed and approved by its Institutional Review Board on 9th May 2019. The study was conducted in compliance with the approved study protocol, the Declaration of Helsinki, 1964, as revised in 2013, and Good Clinical Practice. Highlights: A phase I study of JR-142, a novel long-acting growth hormone, found its weekly injections of 0.15 to 1.0 mg/kg for up to four weeks safe and well tolerated, with a dose-dependent increase in the plasma concentrations of JR-142 and serum IGF-1. JR-142 demonstrated a unique ability to maintain IGF-1 levels in a more favorable range than other long-acting GH therapeutics. These findings need to be substantiated in pediatric GHD patients to establish JR-142 as a useful new therapeutic for long-term treatment.